Related Experiment Video
Updated: May 27, 2026
07:15
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
Published on: July 28, 2020
The management of soft tissue sarcomas
Steven Cutts1, Ferrero Andrea, Raimondo Piana
1James Paget University Hospital, Lowestoft Road, Gorleston, Great Yarmouth, Norfolk NR31 6LA, United Kingdom. stevenfrcs@hotmail.com
Summary
Early referral and specialist care are crucial for managing soft tissue sarcomas. Non-specialist surgery increases recurrence risk; all procedures should occur within Multi Disciplinary Teams (MDTs).
Area of Science:
- Oncology
- Surgical Pathology
Background:
- Soft tissue sarcomas are rare, heterogeneous malignancies originating from mesenchymal cells.
- Management has improved with Multi Disciplinary Teams (MDTs) for bone and soft tissue tumors.
- Recent guideline changes necessitate a review of current soft tissue tumor management strategies.
Purpose of the Study:
- To review current management principles for soft tissue sarcomas.
- To discuss diagnosis, treatment, and the role of adjuvant therapy.
- To emphasize the importance of specialized care in sarcoma treatment.
Main Methods:
- Retrospective review of literature.
- Consultation of recent National Institute for Health and Care Excellence (NICE) guidelines.
- Medline search for existing studies on soft tissue sarcoma management.
Main Results:
- Early and appropriate patient referral is key to successful outcomes.
- Improved survivability is achievable through enhanced medical professional knowledge.
- Surgical responsibility has transitioned to super specialists.
Conclusions:
- Non-specialist excision or biopsy of soft tissue sarcomas increases recurrence risk.
- All invasive procedures for these tumors should be conducted within an MDT setting.
- Specialized multidisciplinary care is essential for optimal soft tissue sarcoma patient outcomes.
